SEC Foi	m 4 FORM	4	UNITED	STAT	ΓES	SI	ECUR	ITIE	ES AND	EX	СНА	NGE C	COMMI	SSION				
					Washington, D.C. 20549											OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					l pursu	Jant	to Section	n 16(a	A) of the Sect	urities	Exchar		SHIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* GERAGHTY JAMES A					2. Issuer Name <b>and</b> Ticker or Trading Symbol Orchard Therapeutics plc [ ORTX ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) Officer (give below)								(give title		Other (s below)	pecify	
C/O ORCHARD THERAPEUTICS PLC 245 HAMMERSMITH ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) LONDON X0 W6 8PV					Form filed by More than One Reporting Person											ting		
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tal	ble I - Non	-Deriva	ative	Se	curities	s Ac	quired, D	ispo	osed o	of, or Be	neficiall	y Owned				
Date				2. Transad Date (Month/Da			2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on 🛛	n Disposed Of (		ies Acquired (A) or Of (D) (Instr. 3, 4 and		nt of s ally ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
							Code	v i	Amount	(A) ( (D)	or Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
			Table II - D ((						uired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	e, Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		le and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	de	v	(A)	(D)	Date Exercisable		iration e	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$0.495	06/14/2023			A		105,000		(1)	06/1	13/2033	Ordinary Shares <sup>(2)</sup>	105,000	\$0.00	105,00	00	D	

## Explanation of Responses:

1. All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

## **Remarks:**

<u>/s/ Frank Thomas, as attorney-</u> <u>in-fact</u>

06/16/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.